Inhibition sélective de la voie MK2 : Données d'un essai clinique randomisé de phase IIa dans l'arthrite rhumatoïde
ACR Open Rheumatol. 2023;5(2):63–70 doi: 10.1002/acr2.11517
Data show that the first-in-class MK2 pathway inhibitor ATI-450 was well tolerated and induced sustained anti-inflammatory efficacy over 12 weeks in patients with moderate-to-severe RA.